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Abstract  
Introduction: Acquired immunodeficiency syndrome (AIDS) is one of the 
most common infectious diseases in the world. It is transmitted via the 
Human Immunodeficiency Virus (HIV-1). So, a HIV-1 vaccine should be 
eff ective in the prevention of virus infection and induces immune responses. 
The main aim of this study was to evaluate the humoral immune induction 
through measuring the expression of interleukin4 (IL-4) in response to 
levamisole, as an adjuvant, with the HIV-1 Nef-p24 fusion protein as an 
immunogenic sequence.  
Materials and Methods: In this study, 56 BalB/c female mice, aged 6 to 8 
weeks were divided into 4 groups. There were 14 mice in each group. Prime 
and Booster injections were arranged in these groups receiving PBS, 
levamisole, Nef-p24, and Nef-p24 along with levamisole (Nef-
p24/levamisole). All injections were performed peritoneally.  
Results: Real-time PCR results showed that IL-4 transcripts level increased 
significantly (P <0.05) in boostered groups, receiving levamisole, Nef-p24, 
and Nef-p24/levamisole compared to primed groups. However, the results of 
ELISA revealed the enhancement in IL-4 expression in levamisole primed 
groups in comparison to Nef-p24/levamisole boostered group.  
Conclusion: The results of the present study showed that the HIV-1 Nef-p24 
fusion protein and levamisole could be considered as effective candidates as 
to increase the expression of IL-4 which may stimulate the humoral immune 
response. 
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1. Introduction 
     Acquired immunodeficiency syndrome 
(AIDS), one of the most common infectious 
diseases in human history, is caused by 
Human Immunodeficiency Virus (HIV) [1]. 
The World Health Organization estimates 
that about 36.7 million people are living 
with HIV in 2015 and 1.1 million people 
lost their lives for that cause [2]. UNAIDS 
(United Nations Programme on HIV/AID) 
has adopted determined targets which are to 
identify HIV-infected population, and to 
provide access to Antiretroviral Therapy 
(ART) for infected the population and viral 
suppression for the population using ART 
[3]. Also Highly Activated Antiretroviral 
Virus medication (HAART) has developed 
quickly; transforming the HIV-1 into a 
controllable chronic infection [4]. While 
global commitment to manage the 
HIV/AIDS epidemic has increased 
considerably in recent years, the virus 
continues to spread with alarming and 
increasing speed. During the past century, 
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vaccination has turned to be the most 
effective medical method in reducing the 
death rate caused by viral factors [5, 6]. 
Although a vast range of alternative 
potential vaccination is available for 
avoidance and therapy, development of HIV 
vaccination strategy is still considered to be 
a serious scientific challenge [7]. On the 
other hand, the development of a vaccine 
for HIV has proved to be very difficult, 
partly because of the complex nature of the 
virus [8]. HIV is highly adaptable because 
of its high mutation rate and there are 
multiple strains belonging to a number of 
different clades [9], so it is probable that a 
multi-component vaccine comprising 
several proteins or peptides will be required 
to invoke broad and powerful immunity. 
Subunit vaccines offer the advantage of 
targeting specific epitopes that lie within 
conserved areas of the virus. Two potential 
antigens, the 24-kDa capsid protein p24 and 
the 31-kDa regulatory protein Nef, are the 
focus of this study. P24 sequence with 159-
173 amino acids plays an important role in 
HIV control through inducing appropriate 
cellular immune response. Nef sequence 
protein with 102-107 amino acids as a 
regulator protein plays a vital role in virus 
replication and pathogenicity. According to 
the available studies, it is expected that a 
combination of these two proteins acts as a 
strong immunogenic sequence in designing 
recombinant HIV vaccines. [10-16]. 
Moreover, Interleukin 4 (IL-4) is a cytokine 
that participates in the regulation of the 
immune system at multiple levels [13]. The 
ability of cytokines to influence HIV-1 
propagation has been studied extensively. 
Levamisole is a synthetic, orally active 
agent that has anthelmintic and 
immunomodulatory properties. Adjuvants 
are chemical or biological compounds 
which induce a non-specific immune system 
against antigen/s that are injected along 
with the compound. Reducing the adverse 
effects of vaccination and stimulating a 
specific type of immunity leads to a vast 
and novel development of adjuvants [11]. 
Adding an adjuvant into a vaccine antigen 
shows several advantages such as dose 
reduction and faster response induction 
[12]. The purpose of current research is to 
evaluate the IL-4 gene expression after 
immunization through Nef-p24 
immunogenic peptide sequences along with 
levamisole adjuvant.  
 
2. Materials and Methods 
2.1 Study Design 
     This study was a true experimental 
research in which the posttest-only control 
group design was selected. All experiments 
were done in summer of 2018 in Genetics 
department of Tehran medical Sciences, 
Islamic Azad University, Iran.  
 
2.2 Preparing Adjuvant and 
Recombinant HIV-1 Nef-p24 Fusion 
Protein 
     The considered recombinant fusion 
protein for this research consisted of Nef 
immunogenic epitope and p24 from HIV-1 
virus. The sequences of these proteins were 
found in PDB site according to a similar 
study [13]. PDB ID for NEF and p24 were 2 
NEF and 4 XFX respectively. By putting 
together the sequences, the following final 
sequence was obtained: 
HSQRRQDILDLWIYHTVEEKAFSPEVI
PMFS  
The recombinant protein with a length of 31 
amino acids and 95% purity was purchased 
from Takapouzist Company, eventually. 
Levamisole adjuvant with 99% purity was 
purchased from Pursina Pharmaceutical 
Company. To prepare the immunogenic 
sequence with the candidate adjuvant, 
recombinant HIV-1 Nef-p24 fusion protein 
was mixed with levamisole adjuvant. The 
mixture was shaken for an hour on a shaker. 
For every 200 µL of levamisole, 2µgr of 
candidate recombinant protein was applied 
[17, 18]. 
 
2.3 Classification and Laboratory 
Animal Treatment 
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     Fifty-six BalB/c female mice were 
purchased from Karaj Pasteur Institute. 
They were kept in an animal laboratory in 
36°C and a suitable air conditioned area. 
Health, having the age between 6-8 weeks 
and equal weight of 25gr for mice were 
considered as study inclusion criteria. Mice 
which were not injected correctly or had 
failed blood sampling, were excluded from 
the experiment. 
Considered mice were classified into four 
main groups for the study. Each group 
consisted of 14 mice. The first group 
received Nef-p24 immunogenic sequence 
with adjuvant (Nef-p24/levamisole). The 
second group received Nef-p24 
immunogenic sequence without adjuvant. 
The third and fourth group received only 
adjuvant and PBS, respectively. All the 
mice were put inside the separate cages. 
The final volume of injection and 
vaccination dose were 50µL and 20µg, 
respectively.  
Injection schedule took place in two shifts 
for each mice. Fourteen days after prime 
injection, booster injection was done for 
half of the mice population using 
peritoneum hypodermic injection. 14 days 
after the first and the second injection, the 
mice were gone under an operation to 
evaluate the immune response, respectively. 
They first were comatose using chloroform. 
To obtain more peripheral blood, a 
sampling syringe was used to collect blood 






     Enzyme-Linked Immunosorbent Assay 
(ELISA) is a commonly used analytical 
biochemistry assay. ELISA is done based 
on the antibody level produced in virus-
infected persons. Here, the method of 
Sandwich ELISA was applied to analyze 
IL-4 protein expression, using anti IL-4 
antibodies labeled with biotin. The purified 
sample used in ELISA was treated based on 
the Bio Assay kit`s instructions. At final 
stage, sample OD was read at 450 nm [13].  
 
2.5 Real Time PCR  
     RNA was extracted from peripheral 
blood using a RNX PLUS kit (Sina Gene 
Company). The extraction was exactly done 
according to the kit protocol and samples 
OD were measured using a Nano drop 
device. Then, cDNA was synthesize by 10 
µL of RNA using Easy cDNA Synthesis 
Kit. The protocol was followed precisely.  
To analyze IL-4 gene expression level, first 
IL-4 and GAPDH (as a positive control) 
gene mRNA sequences were obtained from 
NCBI. Then, the intended primer was 
designed based on the required standards 
using Primer3 software. To identify the 
homolog parts with intended products, 
certain primers were searched in BLAST 
and NCBI to have the product of specific 
target gene. Designed primers were 
purchased from Sina Clone Company 
(Table 1). For Real Time PCR procedure, 
primers and cDNA were mixed based on the 
kit’s procedure. Bioneer device was applied 
for Real-Time PCR and the intended 
schedule was regulated according to Table 
2. 
 
Table 1. GAPDH and IL-4 primers sequence 
Sequence Length  
AACGAGGTCACAGGAGAAGG 02 Interlokin-4 FWR 
TCTGCAGCTCCATGAGAACA 02 Interlokin-4 REV 
GAAGGTGAAGGTCGGAGTGA 02 GAPDH FWR 
AATGAAGGGGTCATTGATGG 02 GAPDH REV 
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2.6 Statistical Analysis 
     The general trial method of the study 
was done in 7 phases. Data were examined 
using the SPSS software ver. 24. Analysis 
of variance (ANOVA) and Tukey’s tests 
(P≤ 0.05) of mean comparison were applied 
to show statistical differences between 
means. Gene expression analysis was done 
based on sample`s OD and Ct, obtained 
from the Real-Time PCR. 
 
3. Results 
Real Time PCR  
     To ensure the accuracy of the primers, a 
PCR was done and one specified band was 
observed (Figure 1A). The amplification 
plot of IL-4 and GAPDH is shown in Figure 
1B. In addition the specificity of the primers 
used in Real-Time PCR was determined 

























Figure1. Real time PCR results. A. PCR gel electrophoresis of IL-4 gene expression. B. IL-4 and GAPDH amplification 
plot. C Melting curve analysis of IL-4 gene. 
 
Expression of IL-4 Gene Transcripts 
     A significant increase in IL-4 transcripts 
level was observed in all boostered groups 
in comparison with primed groups (Figure 
2). A remarkable difference was shown in 
transcription of IL-4 in the groups receiving 
levamisole, Nef-p24 and Nef-
p24/levamisole in their second round of 
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injection. In addition, among the boostered 
groups, IL-4 transcripts level reached the 
highest level in the Nef-p24 group (Figure 
2). 
 
IL -4  g e n e  e x p re s s io n  R e a l T im e  P C R



















































Figure 2. Comparison of IL-4 gene transcripts expression between primed and boostered groups receiving levamisole, 
Nef-p24 and Nef-p24/levamisole in BalB/c female mice based on the control group.  
All data are presented as the means ± SD with n = 3. **, +++ and ×× show significant difference at P ≤ 0.05. 
  
ELISA  
     Data analysis showed the significant 
difference in IL-4 expression in the first 
injected (primed) mice; between group 
receiving levamisole (OD=0.48) and control 
group (OD=0.97) (Figure 3). In fact, IL-4 
protein expression decreased remarkably in 
group receiving levamisole in comparison 
to the control (P<0.05) (×). There was no 
significant difference in IL-4 expression 
between groups receiving Nef-
P24/levamisole (OD=0.95), and Nef-p24 
(OD=0.81) in the primed injection. 
Data comparison between prime and 
booster injected mice showed a significant 
increase in IL-4 expression level in the 
primed control, compared to boostered 
group receiving levamisole (OD=0.71) 
(P<0.001) (+++). Furthermore, a notable 
enhancement in IL-4 expression was 
observed in primed group receiving 
levamisole in comparison with boostered 
receiving Nef-p24/levamisole (OD=0.16) 
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Figure 3. Comparison of IL-4 expression level by ELIZA between primed and boostered groups receiving levamisole, 
Nef-p24 and Nef-p24/levamisole in BalB/c female mice based on the control group. All data are presented as the means ± 
SD with n = 3. ×, and +++ and *** show significant difference at P≤ 0.05 and P<0.001, respectively.  
 
4. Discussion 
     Since HIV viral factor has been 
discovered, several amino acid sequences 
have been proposed as candidate vaccines. 
In the present study, recombinant HIV-1 
Nef-p24 fusion protein was used along with 
levamisole adjuvant to assess the immune 
response in mice by IL-4 gene expression. 
Therefore, Real-Time PCR and ELISA test 
was applied to evaluate the immune 
response. The results of Real Time PCR 
showed a significant enhancement in IL-4 
transcripts expression in boostered groups 
receiving levamisole, Nef-p24 and Nef-
p24/levamisole, compared to primed 
groups. However, the results of ELISA 
cleared the increase in IL-4 expression in 
levamisole primed groups in comparison to 
Nef-p24/levamisole boostered group. It was 
shown that IL-4 as a cytokine takes part in 
the immune system regulation at multiple 
levels [13]. 
In the present study, the Nef-p24fusion 
protein was used as an immunogenic 
sequence. Investigating of the immune 
response produced against each of these 
proteins alone indicated that they could 
induce both cellular and humoral immune 
responses [13]. In a study accomplished by 
Gavioli et al. (2008), Tat protein along with 
complete Freund`s adjuvant was used in the 
first stage and incomplete Freund`s adjuvant 
was used at booster stage. Results showed 
that the adjuvanted fusion peptide induced 
cytokines interferon gamma (IFN-γ) and IL-
4 in the Th1 pattern and increased level of 
cellular immunity [19]. Another research 
was done on surveying Gag, Pol and Nef 
protein in combination with equal amount 
of adjuvant and without any adjuvant. The 
improved cellular immune response was 
evaluated through IFN-γ level induction by 
T-CD4 and T-CD8 cells. [20]. Moreover, 
Kang et al. (2018) studied ENV protein 
along with gp140 adjuvant. Enhanced 
Humoral immunity was evaluated using 
ELISA test for measuring IgG and IgA [21]. 
Mahdavi et al. (2010) conducted a trial on 
immunized BALB/c mice with a pure 
recombinant peptide Gag p24-Nef. Results 
displayed a significant increase in humoral 
immunity level by inducing IgG2a 
antibody, and in cellular immunity by 
cytokines IFN-γ and IL-4 [13]. In addition, 
specified immune responses were 
stimulated in mice when co-immunizing 
with LIGHT (member of TNF family) 
expression plasmids and HIV-1 nef DNA 
vaccine plasmids. It was suggested that Nef 
and LIGHT can increase the humoral 
immunity level [22].  
Also, a research on effectiveness of p24, 
Nef, and p17 as a fusion protein along with 
AS01B adjuvant was done. Results 
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illustrated an increase in both humoral and 
cellular immunity. In this trial, INF-γ was 
measured using ELISA test [23]. It was 
shown that Nef-p24 is a candidate as a 
constituent of a vaccine provided by oral 
boosting, following subcutaneous priming 
by injection of Nef and/or p24 [24]. 
Moreover, Nef peptide and 1MVA vaccine 
showed a strong response in immune 
system. It was proved that Nef-p24 has a 
high level of immunization. In this research, 
IFN-γ, was measured using ELISA [25]. In 
a study a nef expressing DNA was injected 
to mice and GM-CSF cytokine was used to 
increase the immune response. Results 
represented a severe immune response 
towards the Nef through raised level of IL-2 
and IFN-γ [26]. 
It has been noticed that the ratio of 
IgG2a/IgG1 would increase in the 
adjuvanted Nef-p24 immunization group, 
which verified the Th1 profile of immune 
response in this group [13, 27, 28]. 
Structural proteins, such as p24, are good 
candidates for vaccine components because 
of their high conservation [14]. Nef, is an 
indispensable early post-infection 
regulatory protein. Researches in non-
human primates have shown that vaccine 
induced cytotoxic T-lymphocyte responses 
against early proteins, such as Nef, provide 
a degree of protection against pathogenic 
virus challenges [14, 18]. 
On the other hand, in this research 
levamisole was studied as the first adjuvant 
in HIV-1 studies stimulating humoral 
immunity system. In some researches 
levamisole was used as an adjuvant along 
with DNA vaccine and hepatitis B vaccine 
to increase the immunity level in tumor 
cells and patients suffering AIDS (50mg 
twice a day), respectively [17, 29]. 
However, Cazella et al. (2009) conducted a 
trial in which application of levamisole (6.0 
mg/kg of live weight) in rabies-primed 
vaccines did not affect the humoral immune 
system [30]. In another research levamisole 
and hepatitis B vaccine were applied in oral 
form. An enhancement of immunity 
response in the group receiving levamisole 
was obtained. In this study, antibody titer 
was used to measure the immunity level 
[31]. A research done on Salmon showed a 
different result of levamisole. Although 
levamisole adjuvanted vaccine induced 
immune response in fish, this response was 
still less than that of the group with no 
adjuvant [32]. These results indicate that 
levamisole as an adjuvant has a restricted 
range of efficacy. It was shown that 
levamisole triggers dendritic cells by 
binding to Toll-like receptor- (TLR-) 2. 
This adjuvant induces Th1 immune 
response and stimulates production of IL-12 
[17]. 
In the present study, since there was a 
limitation to investigate different doses of 
Nef-p24 and levamisole, it is suggested to 
assess their impact on immune system to 
find their optimum concentrations. 
Moreover, it is necessary to analyze 
humoral immune responses to Nef-p24 and 
levamisole, by expression of other involved 
cytokines. On the other hand, evaluation of 
cellular immune responses to Nef-p24 
immunogenic sequence and levamisole 
along with the presented results might 
introduce them as a new vaccine candidate 
for HIV-1.  
 
5. Conclusion 
     The results of the present study showed that 
HIV-1 Nef-p24 fusion protein and 
levamisole adjuvant, enhanced IL-4 
expression in the injected mice. In fact, our 
results as well as previous studies revealed 
that Nef-p24 along with levamisole could be 
considered as effective candidates to induce 
the humoral immune response by increasing 
the expression of IL-4. It seems that further 
investigations focused at other aspects of 
immune responses are needed. 
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